The Charcot-Marie-Tooth Association (CMTA) announced today that it has entered into a collaboration with Affectis Pharmaceuticals AG to evaluate the efficacy of advanced Affectis compounds in neurological and behavioral models of CMT1A.
The Lead Discovery Center GmbH (LDC) and AstraZeneca have expanded their alliance to discover new medicines for the treatment of human diseases with high unmet medical need.
The Lead Discovery Center GmbH (LDC) and the Helmholtz Centre for Infection Research (HZI) will be working in close cooperation to identify and optimize new drug candidates against methicillin-resistant Staphylococcus aureus (MRSA).
New cancer therapy approach from the German Cancer Consortium (DKTK)
Utilizing shared compound libraries for novel LDC targets
Partners will collaborate to discover lead structures and potential development candidates for novel drug targets
The Max Planck Institute of Biochemistry (MPIB), the Lead Discovery Center GmbH (LDC) and Qurient Co., Ltd have entered into a license agreement providing Qurient with world-wide
The Lead Discovery Center GmbH (LDC) and AstraZeneca have joined forces to discover new medicines for the treatment of human diseases with high unmet medical need.
Six of the world's top translational health research centres today announced that they have come together to form a new Global Alliance of Leading Drug Discovery and Development Centres.
Successful Transfer into Pre-Clinical Drug Development at Bayer Pharma AG
Page 1 of 1